Details for Patent: 8,273,892

Which drugs does patent 8,273,892 protect, and when does it expire?

Patent 8,273,892 protects BAXDELA and is included in two NDAs.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 8,273,892

Title:	Salt and crystalline forms thereof of a drug
Abstract:	A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Inventor(s):	Zhang; Geoff G. Z. (Libertyville, IL), Bradley; Michael F. (Covington, WA), Barnes; David M. (Lake Villa, IL), Henry; Rodger (Wildwood, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	12/763,476
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 8,273,892

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Melinta	BAXDELA	delafloxacin meglumine	POWDER;INTRAVENOUS	208611-001	Jun 19, 2017		RX	Yes	Yes				Y
Melinta	BAXDELA	delafloxacin meglumine	TABLET;ORAL	208610-001	Jun 19, 2017		RX	Yes	Yes				Y

International Family Members for US Patent 8,273,892

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2582954
Denmark	3056492
European Patent Office	1802607
European Patent Office	3056492